The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis

OBJECTIVE: Secukinumab, a new treatment agent, selectively neutralizes interleukin (IL)-17A. It is used in the treatment of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis. It is known that the agents used in the treatment of rheumatic diseases have effects on hematological par...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Rheumatol
Main Authors: Karataş, Ahmet, Gerçek, Aybüke Nisa, Öz, Burak, Gözel, Nevzat, Pişkin Sağır, Rabia, Gür, Mustafa, Koca, Süleyman Serdar
Formato: Artigo
Idioma:Inglês
Publicado em: Medical Research and Education Association 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574766/
https://ncbi.nlm.nih.gov/pubmed/32910771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/eurjrheum.2020.20109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados